Joaquin Mateo joins VHIO to drive translational research against prostate cancer


VHIO is pleased to announce that Joaquin Mateo has just joined us from the Institute of Cancer Research – Royal Marsden NHS Foundation Trust (London), where he developed his career under the mentorship of Johann de Bono, as Principal Investigator of VHIO’s newly established Prostate Cancer Translational Research Group.

Joaquin attended Medical School at the Universitat de Barcelona and completed his medical training in oncology at the Catalan Institute of Oncology (ICO). He obtained his postgraduate degree in Clinical Trial Design in 2010, with particular focus on early phase studies with companion biomarker development. He joined the Drug Development Unit at the Institute of Cancer Research – Royal Marsden NHS Foundation Trust in 2011 for a two-year fellowship under the leadership of Johann de Bono and Stan Kaye, where he worked on first-in-man clinical trials of several PARP inhibitors and compounds targeting the PI3-AKT-mTOR pathway. From 2013, he progressively focused on the design and development of clinical trials for castration-resistant prostate cancer (CRPC).

His main interest centres on the integration of tumour molecular characterisation data into real-time clinical decision-making for patients through multidisciplinary tumour boards, as reflected by his involvement in the setting up of the molecular tumour boards at the Drug Development Unit and Prostate Cancer Targeted Therapy Unit at The Royal Marsden.

After receiving a joint Medical Research Council & Prostate Cancer UK Fellowship award in 2014, he pursued a PhD at The Institute of Cancer Research to advance insights into the prevalence and clinical relevance of germline and somatic DNA repair defects in the progression of prostate cancer and how to therapeutically exploit these aberrations. In 2016, he received a Prostate Cancer Foundation Young Investigator Award to continue working on the development of PARP inhibitors, platinum-based therapies and companion predictive biomarkers for CRPC patients.

His significant contribution to the field has already resulted in his (co) authorship of several manuscripts published in top-tier journals including The New England Journal of Medicine, Clinical Cancer Research, Cell, and Cancer Discovery.

As Principal Investigator of VHIO’s Prostate Cancer Translational Research Group, Joaquin will lead research aimed at translating prostate cancer genotypes into phenotypes and a clinically-relevant classification of the disease. He will also seek to build a precision medicine core for prostate cancer patients.

For more information please visit his group and PI pages:

On behalf of VHIO, we warmly welcome Joaquin as an additional talent to VHIO´s team of cancer researchers and clinical investigators.